The IMPACT trial38 showed a statistically significant 85% reduction of mean cancer cell Ki-67 positivity rate in the HER2-negative group compared to a 45% reduction in the HER2-positive group despite good clinical responses seen in the HER2-positive group, which suggests rapid emergence of HER2-mediated resistance. This evidence concerns the gene ERBB2 and cancer.